What stage does Esperante Ventures invest at?

Esperante Ventures invests at the Seed, Series A stages.

What is Esperante Ventures's typical check size?

Esperante Ventures typically writes checks of $540K – $5.4M.

What sectors does Esperante Ventures focus on?

Esperante Ventures focuses on Biotech, Medical Devices.

Where is Esperante Ventures located?

Esperante Ventures is headquartered in London, GB.

Esperante Ventures

Venture capital

London · Seed–Series A · 1 people tracked

Also known as Esperante

★ Follow + Add to CRM ⤳ Find an introduction

Find your way into Esperante Ventures

Each arrow is one introduction. Sign up to fill in the first one.

40 people can intro you to Dean

Ask Amanda Wooding to introduce you to Dean Slagel

You →Amanda · together at Ferring Pharmaceuticals →Dean

Your email: who you already know at Esperante Ventures, and who your contacts know
2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Esperante Ventures team
Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

✨ Fox Verdict

Investment thesis

Esperante Ventures is a venture investment firm owned by C&P Group Holdings, a private holding company focused on life sciences.

Invests inBiotech Medical Devices France Israel London Switzerland United Kingdom United States

Source: firm website, verified Jul 31, 2026.

Leave your own feedback

Stage

Seed–Series A

Check

$540K – $5.4M

London, GB

Instruments

Equity

Founded

2004

Tracked investments

Acquisitions

Team · 1 people

from public directories

Dean Slagel· Managing Director· United Kingdomin

Dean Slagel is Managing Director at Marom Advisory Partners and was the founding Managing Director of Esperante Ventures, where he oversaw investments of EUR 500k–5m in mid-to-late stage therapeutics and commercial-stage diagnostics across North America, Europe and Israel. His track record includes 25+ portfolio investments, five exits and four public listings, among them the IPOs of Cara Therapeutics, Altimmune and Medicenna Therapeutics, and he has served as investor or non-executive director on nine biotech boards. Earlier, he held business development roles at Ferring Pharmaceuticals in Paris and Copenhagen and at Tillotts Pharma in Basel, covering licensing and international market development in regions including Mexico, Russia, Israel, Saudi Arabia and Canada.

dean.slagel@esperante.com

What they invest in

from 4 of 4 portfolio companies

Biotech ×4Digital Health ×4Medical Devices ×4Healthtech ×2

HQs:Germany×1United Kingdom×1United States×1

Investments · 4 tracked

founders shown can be your intro path

By year:2024 · 1 2023 · 1 2022 · 1 2019 · 14 dated

Acousiaacousia.comJan 2024

Acousia Therapeutics develops small-molecule drug candidates with a dual mode of action for treating acute and chronic sensorineural hearing loss (SNHL), targeting outer hair cells in the inner ear to preserve and enhance natural hearing.

BiotechDigital HealthHealthtechMedical DevicesTübingen, DE

Hubert Löwenheim(Founder / Board Member)

Co-investorsBoehringer Ingelheim Venture Fund KfW Creathor Ventures LBBW Venture Capital GmbH

AMLo Biosciencesamlo-biosciences.com 𝕏May 2022

AMLo Biosciences develops prognostic and companion diagnostic tests for cancer patients, initially focusing on melanoma and oropharyngeal squamous cell carcinoma.

BiotechDigital HealthMedical DevicesNewcastle upon Tyne, GB

Penny Lovat(Chief Scientific Officer)in

Co-investorsConduit Connect Future Planet Capital Milltrust International Group Northstar Ventures

Spiral Therapeuticsspiraltx.com inAug 2023

Spiral Therapeutics is a clinical-stage pharmaceutical company developing therapies for balance disorders and hearing loss using its Minimally Invasive Cochlear System (MICS) drug delivery platform.

BiotechDigital HealthHealthtechMedical DevicesSouth San Francisco, US

Hugo Peris(Founder & CEO)inEugene de Juan(Executive Officer, Director)Lawrence Fritz(Director)

BoardWARREN THALER(Director)JEAN-FREDERIC PAULSEN(Director)Guy Nohra(Director)in

Co-investorsCatalio Capital Management Inveready Technology Investment Group Lifelink Alta Partners Camden Partners

Versantisversantis.com inSep 2019 · $16.1Macquired by GENFIT

GENFIT is a biopharmaceutical company developing therapies for rare, life-threatening liver diseases, with a focus on acute-on-chronic liver failure (ACLF), hepatic encephalopathy (HE), cholangiocarcinoma, urea cycle disorders, and organic acidemias.

BiotechDigital HealthMedical Devices

Co-investorsOCCIDENT Verve Ventures Healthequity redalpine

Exits · 1

1 acquisitions

Versantisacq. by GENFIT

Portfolio news

latest coverage across their companies

Spiral Therapeutics Raises $27M in Series B Funding

Spiral Therapeutics · finsmes.com · Apr 14, 2026

Frequently asked questions

What stage does Esperante Ventures invest at?: Esperante Ventures invests at the Seed, Series A stages.
What is Esperante Ventures's typical check size?: Esperante Ventures typically writes checks of $540K – $5.4M.
What sectors does Esperante Ventures focus on?: Esperante Ventures focuses on Biotech, Medical Devices.
Where is Esperante Ventures located?: Esperante Ventures is headquartered in London, GB.

Similar investors

ACT Venture Capital

ACT Venture Capital is an independent Irish venture capital firm that invests €1 million to €15 million in growth-stage private companies, with capacity for larger commitments through syndicated rounds.

$1.1M – $16.2M

Amadeus Capital Partners

Amadeus Capital Partners is a UK-based deep tech venture capital firm founded in 1997 that invests in technology companies from seed to growth stage. Since inception it has backed over 200 companies and raised more than $1.3 billion.

$50K – $12.7M

B Capital Group

B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.

$10M – $50M

Breyer Capital

Breyer Capital is a venture capital firm that backs high-impact entrepreneurs, making strategic investments guided by founder passion and its network of experienced investors.

$500K – $10M

Canaan Partners

Canaan Partners is a venture capital firm with over 30 years of history, backing companies across technology and healthcare sectors through close, hands-on partnerships with founders.

$500K – $20M